Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
BLENREP is the fifth major medicine approval for GSK in 2020
Read more -
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
Discussions relate to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system
Read more -
Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.
Read more -
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
Read more -
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
Read more -
GSK receives positive CHMP opinion recommending approval of belantamab mafodotin for the treatment of relapsed and refractory multiple myeloma
If approved, it will be the second major regulatory milestone for GSK’s oncology portfolio this year.
Read more -
COVID-19 prompts increased focus on self-care, with Europeans taking their health more seriously to relieve pressure on healthcare systems
New research shared by GSK Consumer Healthcare and IPSOS
Read more -
GSK and CureVac announce strategic mRNA technology collaboration
Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
Read more -
GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma
FDA ODAC voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin
Read more -
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir
Read more -
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine.
Read more -
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices
Findings presented showed healthcare providers perceived implementation of the treatment as feasible and appropriate for people with HIV.
Read more -
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
Read more -
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
ViiV Healthcare will present over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), 6-10 July.
Read more -
GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease
Approval marks a significant step in GSK’s global efforts to help patients with anaemia due to chronic kidney disease (CKD).
Read more -
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin
Read more -
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019
Read more -
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
Read more -
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
Read more -
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
